All News

Company consolidates its consultancy portfolio into a single, comprehensive offering.

Lofexidine is an investigational drug under development to mitigate symptoms associated with opioid withdrawal.

Company's additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters forms a fully dedicated centre of excellence for clinical research and quality assurance capabilities.

Company says it is determined to work collaboratively to find a solution.

Global emerging problem and new preventive solutions against tick-borne diseases from ICB Pharma- KICK THE TICK® expert.

Distribution agreement covers countries in the EEA and Switzerland.

Midatech on track to start clinical development with MTD201 in Q4 2017.

The Chinese biopharmaceutical company acquires the Canadian biomanufacturing business of Therapure.

Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals.

Step towards strategic alignment of R&D resources to Healthcare priorities.

Only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive AML.

StemFit Basic02 offers superior and stable growth performance, high colony forming efficiency and robust scalable cell expansion.

Patheon's CDMO capabilities coupled with Thermo's clinical trials services and bioproduction technologies expected to make Thermo and "even stronger partner" for its pharmaceutical and biotech customers.

MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.

ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.

Expansion comes as a result of increased industry demand to better understand and characterize APIs and process intermediates at the clinical stage.

Resubmission package will include new safety and efficacy data.

Kymriah approvaed for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.

First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor.

Volume expected to remain somewhat constrained into the first quarter of fiscal 2018.

FDA cites two manufacturing concerns.

Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.

We have recently opened Offices in China, Japan and the United Kingdom. We have full time Employees in the Overseas Offices. New products are under developments for various applications.

Collaboration to focus on a disease target in Parkinson's disease with Berg's Interrogative Biology technology.

No evidence of a leveling off of effect and no new safety concerns were identified in this analysis.

An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio.

Biogen becomes the first company with approved biosimilars for the three most prescribed anti-TNF biologic treatments in Europe.

Complaint alleges Teva failed to disclose the poor performance of its US generics business and the subsequent goodwill impairment charge stemming from the company’s purchase of Actavis Generics.

Cyltezo approved for the treatment of multiple chronic inflammatory diseases.

Presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk.

Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years.

Appointments come as global leader in contract topical and transdermal pharmaceutical development benefits from increased revenues.

Mylan granted an exclusive license by Otsuka to prioritize access to Deltyba in South Africa and India.

Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children.

Establishes Charles River as a premier source for CNS contract research services.

Data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults.

Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.

Collaboration grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two additional programs, targeting vaccines against hepatitis B virus and the human immunodeficiency virus.

Partnership to target multiple serious diseases using real world data studies.

Investment is in response to increased market for spray drying and capsule filling for dry powder inhalers.

Comapny has created a novel formulation to produce a product prototype containing 300 mg of Isoniazid, that is both rapidly dissolving and mucoadhesive.

Investment will fund a new office in Boston, US, an extension of its UK facility at the Oxford Science Park, and R&D capabilities to increase its intellectual property portfolio.

Models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer.

Esomeprazole Strontium DR capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor, indicated for adults for the treatment of gastroesophageal reflux disease and other gastrointestinal conditions.

Eliquis clinical data include results from a Phase IV trial to be featured in late-breaking science sessions,

Study demonstrates that a complex consisting of tobacco mosaic virus and vcMMAE can kill cancer cells.

Company been able to clarify and resolve a number of the questions raised by the FDA.

Mylan will reclassify EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products effective as of 1 April 2017.

Orion's workflow tools will help Pfizer's efforts to deliver potential breakthrough therapies for patients.

Hikma granted the exclusive rights to manufacture and commercialise three of Takeda’s leading primary care product families.

This month in Pharmaceutical Manufacturing and Packing Sourcer, Verify Brand’s CEO, Michael Howe, addresses how Europe’s Falsified Medicines Directive (FMD) not only provides health and safety benefits to patients, it also presents an opportunity ...

Employees and capabilities will be integrated into Evotec's global drug discovery group to maximise commercial synergies.

Agreement convers the clinical application of Vectura's proprietary smart nebuliser technology to deliver Dynavax's investigational immunotherapeutic agent to lung cancer patients.

Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.

Assay-ready kits will incorporate fully-validated, industry-leading recombinant antibody technology for high throughput research.

The Asian pharma event surpasses 55,000 visits with more than 10,000 overseas visits.

Major pharma manufacturer delivers critical drugs to a leading children's hospital.

Co-exclusive global licence covers manufacture and integration of CEGX TrueMethyl technology for oxidative bisulfite sequencing with Targeted Methylation and NuGEN Ovation Methyl-Seq systems.

Lifitegrast, if approved, would be the first and only new class treatment to address the signs and symptoms of dry eye disease in adults in Europe.

Phase III study fails to meet its primary endpoint.

Inotersen on track for marketing authorization filings this year.

Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.

The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.

The two patents represent the next generation of SM-88, joining tyrosine and melanin into a potentially more potent combination.

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

NIH-led clinical trial suggests that drug slows progression of rare neurological disease.

Vyxeos represents the first new chemotherapy advance in more than 40 years for these adults with AML.

Company is first to offer innovative, reduced-dose HIV treatment in India.

CDSCO certification has improved international repute of India, but domestic companies call for urgent Government support to invest in API facilities.

Transaction is expected to close during Q4 2017, before which a new trade name will be selected for the Business.

Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.

Company also becomes the first solution provider to achieve 100 pharmaceutical and contract manufacturers live and ready for serialization.

Small nimble biotechs to introduce a ‘golden age’ of next generation therapies such as CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors.

Company alleges infringement of two patents.

Decision secures access to Erbitux for new patients in England with oral cavity tumours.

Investment will increase the company's flexibility in meeting both existing and future customer demands.

Project also includes reconfigure the existing small-scale manufacturing area providing a single high-containment building to support early-stage development and manufacturing.

The company's NanoTherm therapy makes it possible to combat the tumour from within, while sparing surrounding healthy tissue.

14 new injection-molding machines and significant increase in efficiency and energy savings.

Contract dispute relates to an agreement entered into among Endo International, Penwest Pharmaceuticals and Impax.

The smart sensor to convert inhalers into connected devices to help patients with Asthma or Chronic Obstructive Pulmonary Diseases (COPD).

Mylan's TLD is the first fixed-dose combination of its kind to be offered to patients being treated for HIV/AIDS.

This knowledge could speed the development of a new category of drugs.

SP Scientifc's ControLyo Central is a suite of online resources to help freeze dried parenterals manufacturers.

Federal judge enters consent decree against outsourcing facility Isomeric Pharmacy Solutions.

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations complements Captek’s offerings.

Life-extending pancreatic cancer medicine to be made available immediately on the NHS.

Bolt-on acquisition adds value to other areas of Lonza’ business, including Health & Nutrition ingredients and excipients.

Romaco will additionally show Innojet process technology and Kilian services at POWTECH.

Gains full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.

EP Vantage releases half-year reviews of pharma & biotech and medtech performance.

Designation given for initial treatment of people with ALK-positive lung cancer.

The launch represents a major step towards therapeutic use of CRISPR.

Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

RESTEC to organise a stand-alone IPhEB exhibition in Russia from 2018 onwards.

Baxter plans to invest in further increasing Claris Injectables’ capacity and capabilities, including adding new aseptic manufacturing and lyophilization.

Company can now offer solutions for serialized receiving, picking, shipping, returns, deactivation, aggregation, de-aggregation, label printing and tag management of pharmaceutical products.

From the aggregation of Alfa Wassermann and Sigma Tau comes Alfasigma, a new company, also in Contract Manufacturing, which inherits the values that have always inspired Alfa Wassermann Contract Manufacturing: quality, technology, versatility and relia...

Guide aims to help the operator understand the complex protocols and heavily regulated procedures associated with pharmaceutical cleanrooms.

Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.

The merger enables STA to advance NCEs from pre-clinical stage to New Drug Application and to market faster and more efficiently for pharma and biotech customers.

Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.

Dalton Pharma Services is preparing glass vials in three varying dose formulations for the clinical kits needed to support the Phase I safety trial for AB569 at the CVAMC later this year.

First study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.

Collaboration aims to maximize the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumor types.

The new facilities enable to company to further grow and flourish.

First Molecule to Complete the Development-to-Launch Cycle within PCI’s Contained Manufacturing Facility.

PCI Pharma Services has announced its first client product to move from clinical development to US commercial launch.

The mPath bioreactor control system is the first to be developed and delivered by a technology supplier specifically for their product line, allowing full access to bioreactor capabilities that current commercial solutions cannot provide.

The CPHI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters.

Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola.

Dermatology unit is rebranded Ortho Dermatologics.

Company launches Ibex innovation in biological development and manufacturing.

Thermo's Samco Clicktainer vials provide secure and reliable sample collection and transport.

First generic prequalification for sofosbuvir tablets.

New approval for treatment of active psoriatic arthritis (PsA).

Vertex now has worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

AI thought to have massive potential to reduce the cost associated with the discovery of new drugs.

40% of industry professionals admit they are not clear about the global requirements for serialization.